Mizuho analyst Graig Suvannavejh raised the firm’s price target on Apellis (APLS) to $20 from $19 and keeps a Neutral rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis price target lowered to $18 from $20 at Wedbush
- Apellis price target lowered to $44 from $45 at Citi
- Balanced Outlook on Apellis: Near-Term Revenue Uncertainty and Developing Long-Term Upside Justify Hold Rating
- Apellis price target raised to $48 from $45 at H.C. Wainwright
- Apellis Pharmaceuticals: Buy Rating Supported by Blockbuster Empaveli Potential, Sustainable Syfovre Growth, and Expanding Kidney Franchise